115 related articles for article (PubMed ID: 3516953)
1. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer.
van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Devilhena M; Raposo S; Leonor J; Schraub S; Chenal C; Barthelme E
Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):587-91. PubMed ID: 3516953
[TBL] [Abstract][Full Text] [Related]
2. Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group.
Van den Bogaert W; van der Schueren E; Van Tongelen C; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
Radiother Oncol; 1985 Feb; 3(2):139-44. PubMed ID: 3983422
[TBL] [Abstract][Full Text] [Related]
3. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
Van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1649-55. PubMed ID: 7153077
[TBL] [Abstract][Full Text] [Related]
4. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; Van Glabbeke M
Radiother Oncol; 1995 May; 35(2):91-9. PubMed ID: 7569030
[TBL] [Abstract][Full Text] [Related]
5. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: prognostic factors.
Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; van Glabbeke M
Radiother Oncol; 1995 May; 35(2):100-6. PubMed ID: 7569017
[TBL] [Abstract][Full Text] [Related]
6. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
Fazekas J; Pajak TF; Wasserman T; Marcial V; Davis L; Kramer S; Rotman M; Stetz J
Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1155-60. PubMed ID: 3301758
[TBL] [Abstract][Full Text] [Related]
7. Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck.
Panis X; Nguyen TD; Froissart D; Demange L
Int J Radiat Oncol Biol Phys; 1984 Oct; 10(10):1845-9. PubMed ID: 6386760
[TBL] [Abstract][Full Text] [Related]
8. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of head and neck cancer. MRC working party on misonidazole in head and neck cancer.
Br J Radiol; 1984 Jul; 57(679):585-95. PubMed ID: 6329395
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
Lee DJ; Pajak TF; Stetz J; Order SE; Weissberg JB; Fischer JJ
Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):465-70. PubMed ID: 2646255
[TBL] [Abstract][Full Text] [Related]
10. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer.
Sealy R; Cridland S; Barry L; Norris R
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1343-6. PubMed ID: 3531113
[TBL] [Abstract][Full Text] [Related]
11. The treatment of locally advanced head and neck cancer with misonidazole, hyperbaric oxygen and irradiation: an interim report.
Sealy R; Cridland S
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1721-3. PubMed ID: 6384161
[TBL] [Abstract][Full Text] [Related]
12. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
13. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
Awwad HK; Barsoum M; El Merzabani M; Omar S; El Badawy S; Ezzat S; El Baki HA; Zaki A
Am J Clin Oncol; 1983 Feb; 6(1):91-7. PubMed ID: 6301258
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial.
Simpson JR; Bauer M; Perez CA; Wasserman TH; Emami B; Doggett RL; Byhardt RW; Phillips TL; Mowry PA
Int J Radiat Oncol Biol Phys; 1989 Jun; 16(6):1483-91. PubMed ID: 2542197
[TBL] [Abstract][Full Text] [Related]
15. A report on misonidazole in randomized trial in locally advanced head and neck cancer.
Sealy R; Williams A; Cridland S; Stratford M; Minchinton A; Hallet C
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):339-42. PubMed ID: 7050035
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
[TBL] [Abstract][Full Text] [Related]
19. Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group.
Hatlevoll R; Lindegaard KF; Hagen S; Kristiansen K; Nesbakken R; Torvik A; Ganz JC; Mella O; Rosengren B; Ringkjöb R
Cancer; 1985 Jul; 56(1):41-7. PubMed ID: 2988737
[TBL] [Abstract][Full Text] [Related]
20. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
